Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The Peptide Innovation for Early Diabetes Treatment (PIONEER) 12 trial was a randomised, double-dummy, active-controlled, parallel-group, Phase IIIa trial conducted over 26 weeks at 90 sites across the China region (including mainland China, Taiwan and Hong Kong) and five other countries.

Treatment allocation was masked to both participants and investigators.

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

The Semaglutide group and the comparison group ran side by side rather than switching.

The timeline in the abstract includes 26 weeks.

Randomisation was stratified according to whether participants were from the China region or elsewhere.

The primary endpoint was change in HbA1c from baseline to week 26.

The confirmatory secondary endpoint was change in body weight (kg) from baseline to week 26.

All randomised participants were included in the full analysis set (FAS).

What Was Measured

The subject headings attached to it are Blood Glucose, China, Diabetes Mellitus, Type 2, East Asian People, Glucagon-Like Peptides, Glycated Hemoglobin and Hypoglycemic Agents.

The authors tagged it with the keywords GLP-1 analogue, Glycaemic control, Incretin therapy, Phase III, Semaglutide and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Semaglutide over 26 weeks.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetologia), a journal based in Germany.

More context: the Semaglutide compound page, all human trials.